ES8205398A1 - Un procedimiento para la preparacion de derivados de hidan- toina - Google Patents

Un procedimiento para la preparacion de derivados de hidan- toina

Info

Publication number
ES8205398A1
ES8205398A1 ES504103A ES504103A ES8205398A1 ES 8205398 A1 ES8205398 A1 ES 8205398A1 ES 504103 A ES504103 A ES 504103A ES 504103 A ES504103 A ES 504103A ES 8205398 A1 ES8205398 A1 ES 8205398A1
Authority
ES
Spain
Prior art keywords
same
hydantoin derivatives
atom
hydrogen atom
medicines containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES504103A
Other languages
English (en)
Other versions
ES504103A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of ES504103A0 publication Critical patent/ES504103A0/es
Publication of ES8205398A1 publication Critical patent/ES8205398A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE HIDANTOINA. LOS DERIVADOS DE HIDANTOINA DE FORMULA GENERAL (I), DONDE X1, Y X2 SON ATOMOS DE HIDROGENO, ATOMOS DE HALOGENO, UN GRUPO ALCOHILO INFERIOR O ALCOXI INFERIOR; Y ES UN ATOMO DE OXIGENO O DE AZUFRE; R1 Y R2 SON ATOMOS DE HIDROGENO, GRUPOS ALCOHILO INFERIOR O FENILO Y "N" ES 0 O 1, SE PREPARAN POR CONDENSACION DE UN COMPUESTO DE FORMULA (II), UN CIANURO DE METAL ALCALINO, TAL COMO CIANURO DE SODIOCIANURO DE POTASIO, Y CARBONATO DE AMONIO, LLEVANDOSE A CABO LA REACCION A UNA TEMPERATURA DE 50-150 C Y DURANTE UN PERIODO DE TIEMPO COMPRENDIDO ENTRE CUATRO HORAS Y CUATRO DIAS. SE UTILIZA PARA EL TRATAMIENTO Y LA PREVENCION DE LOS DIVERSOS SINTOMAS CRONICOS QUE ACOMPAÑAN A LA DIABETES MELLITUS.
ES504103A 1980-07-21 1981-07-20 Un procedimiento para la preparacion de derivados de hidan- toina Expired ES8205398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP55098695A JPS5745185A (en) 1980-07-21 1980-07-21 Hydantoin derivative and its preparation

Publications (2)

Publication Number Publication Date
ES504103A0 ES504103A0 (es) 1982-06-01
ES8205398A1 true ES8205398A1 (es) 1982-06-01

Family

ID=14226632

Family Applications (1)

Application Number Title Priority Date Filing Date
ES504103A Expired ES8205398A1 (es) 1980-07-21 1981-07-20 Un procedimiento para la preparacion de derivados de hidan- toina

Country Status (14)

Country Link
US (3) US4540704A (es)
JP (1) JPS5745185A (es)
BE (1) BE889698A (es)
CA (1) CA1167447A (es)
CH (1) CH651568A5 (es)
DE (1) DE3128606A1 (es)
DK (1) DK157301C (es)
ES (1) ES8205398A1 (es)
FR (1) FR2487353B1 (es)
GB (1) GB2080304B (es)
IT (1) IT1194143B (es)
NL (1) NL8103432A (es)
PH (1) PH17460A (es)
SE (1) SE454778B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
GB2132484B (en) * 1982-12-23 1986-07-02 Tampax Ltd Tampon applicator
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
ATE37371T1 (de) * 1984-08-20 1988-10-15 Pfizer Verfahren zur herstellung asymmetrischer hydantoine.
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US4666931A (en) * 1984-12-29 1987-05-19 Kaken Pharmaceutical Co., Ltd. Benzofuran derivatives useful in treating diabetic complications
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
US4853410A (en) * 1986-01-17 1989-08-01 Pfizer Inc. Hydroxyacetic acid derivatives for the treatment of diabetic complications
JPS6357588A (ja) * 1986-08-28 1988-03-12 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤
EP0264586B1 (en) * 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US4841079A (en) * 1987-08-07 1989-06-20 Pfizer, Inc. Process for the production of asymmetric hydantoins
JP2708507B2 (ja) * 1988-04-07 1998-02-04 株式会社三和化学研究所 （ｄ）‐６‐フルオロ‐２，３‐ジヒドロ‐２’，５’‐ジオキソ‐スピロ［４Ｈ‐１‐ベンゾピラン‐４，４’‐イミダゾリジン］‐２‐カルボキサミド誘導体、これらの製法及び用途
US4987231A (en) * 1989-08-04 1991-01-22 Pfizer Inc. Optical resolution method for 3R-(3-carboxybenzyl)-6-(5-fluoro-2-benzothiazolyl)methoxy-4R-chromanol
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
US4980357A (en) * 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
CA2113818A1 (en) * 1991-08-28 1993-03-18 Robert C. Gadwood Spirocyclic benzopyran imidazolines
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US7386401B2 (en) * 1994-11-21 2008-06-10 Phatrat Technology, Llc Helmet that reports impact information, and associated methods
US6539336B1 (en) * 1996-12-12 2003-03-25 Phatrat Technologies, Inc. Sport monitoring system for determining airtime, speed, power absorbed and other factors such as drop distance
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
EP1598054B1 (en) * 1997-04-15 2011-03-16 Csir Non-therapeutic methods of suppressing appetite
US6077849A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antidiabetic agents
AU754989B2 (en) * 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
AU2002215160A1 (en) 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US8158667B2 (en) 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
JP2010520913A (ja) 2007-03-12 2010-06-17 サズセ アーペーエス ルイボスの抗糖尿病性抽出物
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
WO2010065024A1 (en) * 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
PT2406240E (pt) 2009-03-13 2016-02-24 Boehringer Ingelheim Int Inibidores de beta-secretase
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AU2011348074B2 (en) 2010-12-23 2016-04-28 The Board Of Regents Of The University Of Texas System Methods for treating COPD
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
WO2014052398A1 (en) 2012-09-28 2014-04-03 Vitae Pharmaceuticals, Inc. Inhibitor of beta-secretase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US418729A (en) * 1890-01-07 Cultivator
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4147795A (en) * 1977-02-11 1979-04-03 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
FR2455046A1 (fr) * 1979-04-25 1980-11-21 Science Union & Cie Nouvelles hydantoines, leur procede de preparation et leur emploi comme medicament

Also Published As

Publication number Publication date
US4874869A (en) 1989-10-17
JPS6332793B2 (es) 1988-07-01
DE3128606A1 (de) 1982-05-13
FR2487353B1 (fr) 1986-03-07
ES504103A0 (es) 1982-06-01
US4780472A (en) 1988-10-25
JPS5745185A (en) 1982-03-13
DK323281A (da) 1982-02-26
DK157301B (da) 1989-12-04
IT1194143B (it) 1988-09-14
GB2080304A (en) 1982-02-03
NL8103432A (nl) 1982-02-16
FR2487353A1 (fr) 1982-01-29
CH651568A5 (de) 1985-09-30
DK157301C (da) 1990-05-07
US4540704A (en) 1985-09-10
CA1167447A (en) 1984-05-15
BE889698A (fr) 1982-01-22
DE3128606C2 (es) 1992-04-23
IT8123026A0 (it) 1981-07-20
SE454778B (sv) 1988-05-30
GB2080304B (en) 1984-02-01
SE8104456L (sv) 1982-01-22
PH17460A (en) 1984-08-29

Similar Documents

Publication Publication Date Title
ES8205398A1 (es) Un procedimiento para la preparacion de derivados de hidan- toina
ES473074A1 (es) Un procedimiento para la preparacion de derivados de tieno- tiacina
ES8400737A1 (es) "un procedimiento para preparar derivados de nicotinamida".
DE3069408D1 (en) 5-oxo- and 5-thioxoproline derivatives, process for their production and pharmaceutical compositions containing them
PT71306B (en) Process for preparing novel cyclic imidazole cyanoguanidines
ES8300699A1 (es) Procedimiento para la preparacion de derivados del indol.
ES463803A1 (es) Procedimiento para la produccion de hidroxilaminas o-alqui- ladas.
GB2134107B (en) Therapeutic compounds
ES481551A1 (es) Procedimiento de preparacion de nuevos compuestos bis (ari- loxicarboxilicos).
DE3267188D1 (en) Hydroxybenzylamino-aryl compounds, process for preparing and pharmaceutical compositions containing the same
ES8604960A1 (es) Procedimiento para preparar derivados de 1,6-naftiridina
ES8202818A1 (es) Un procedimiento para preparar derivados de tetrazolilcuma- rina
ES8200100A1 (es) Procedimiento para la obtencion de un 1,1-dioxido de 6h-1,2,4,6-tiatriazina
HUT42091A (en) Process for production of derivatives of tetrahydrobeta-carbolins and medical preparatives containing thereof
ES8104247A1 (es) Procedimiento para la preparacion de 3-alcoxi-6-alquiliden- hidracionopiridacina
ES8207505A1 (es) Procedimiento para la preparacion de derivados de fenoxi- aminopropanol substituidos
ES8308329A1 (es) "un metodo de preparar derivados de oxotienobenzoxepina".
ES8401957A1 (es) Procedimiento de preparacion de derivados del acido 2-tiofen-acetico.
CH655824GA3 (es)
ES441054A1 (es) Procedimiento de preparacion de nuevos derivados tiazolicos organofosforados.
ES8801542A1 (es) Procedimiento para preparar compuestos arilsulfonicos.
ES8300826A1 (es) Procedimiento para la obtencion de colorantes de azufre
CH609678A5 (en) Process for the preparation of acetamidoximes
ATE32893T1 (de) Spirobenzofuranone, deren herstellung und verwendung.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970612